Influence of the β-blocker nebivolol on left ventricular function in patients with chronic heart failure;Beeinflussung der linksventrikulären funktion durch nebivolol bei patienten mit chronischer herzinsuffizienz NYHA-klasse II-III: Eine pilotstudie

Medizinische Klinik

Volumn 98, Issue 1, 2003, Pages 1-6

  Wolf, Sabine C ^b   Buck Müller, Nina ^b   Görner, Sandra ^b   Risler, Teut ^b   Brehm, Bernhard R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

blocker; Heart failure; Left ventricular function

Indexed keywords

BISOPROLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ERGOMETRY; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BENZOPYRANS; DATA INTERPRETATION, STATISTICAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ETHANOLAMINES; EXERCISE TEST; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; STROKE VOLUME; TIME FACTORS; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 0346034704     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1223-7     Document Type: Article

References (25)

1. Effect ofmetoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
2. The Cardiac Insufficiency Bisoprolol Study 11 (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
3. A trial ofthe beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
4. Böhm M, Maack C. Behandlung der Herzinsuffizienz mit β-Blockern - Mechanismen und Klinische Ergebnisse. In: Dominiak P, Heusch G, Hrsg. Betablocker im neuen Jahrtausend. Darmstadt: Steinkopff, 2001:24-38.
5. Brehm BR, Bertsch D, Wolf SC. Nebivolol hemmt die Proliferation sowohl von humanen koronararteriellen glatten Muskelzellen als auch von Endothelzellen und steigert die NO-Freisetzung. Perfusion 1998;11:475-84.
6. Brehm BR, Wolf SC, Bertsch D, Klaussner M, Wesselborg S, Schuler S, Schulze-Osthoff K. Effects of nebivolol on proliferation and apoptosis on human coronary artery smooth muscle and endothelical cells. Cardiovasc Res 2001;49:430-9.
7. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, van Grosel E, Heemskerk JW, Egbrink MG, van Breda E, Reneman RS, van Der Zee R. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-84.
8. Clements IP, Miller WL. Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy. Am Heart J 2001;141:259.
9. Clements IP, Miller WL, Olson LJ. Resting heart rate and cardiac function in dilated cardiomyopathy. Int J Cardiol 1999;72:27-37.
10. Cockeroft JR, Chowienczyk PHJ, Brett SE, Chen CP, Dupont AG, Van Nueten I, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for L-arginin/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
11. De Cree J, Cobo C, Geukens H, Verhaegen H. Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol. Angiology 1990;41:95-105.
12. De Cree J, Geukens H, Cobo C, Verhaegen H. Subacute hemodynamic effects of nebivolol in man at rest and during exercise. Angiology 1987;38:440-8.
13. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287:883-9.
14. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
15. Janssen PM, Zeitz O, Hasenfuss G. Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. Eur J Pharmacol 1999;366:223-32.
16. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, Clark A. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-7.
17. Love MP, McMurray JJ. Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res 1996;31:665-74.
18. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000;101:142-7.
19. McNeely W, Goa KL. Nebivolol in the management of essential hypertension. Drugs 1999;57:633-51.
20. Melin JA, Piret LV, Vanbutsele RJM, Rousscau MF, Cosyns J, Brasseur LA, Beckers C, Detry JM. Diagnostic value of exercise electrocardiography and thallium myocardial scintigraphy in patients without previous myocardial infarction: a bayesian approach. Circulation 1981;63:1019-24.
21. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
22. Van Bortel LM, van Baak MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drug Ther 1992;6:239-47.
23. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens 1997;11:813-9.
24. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.
25. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3-month) effects of a new betablocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-100.